EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

Kris V Kowdley, Christopher L Bowlus, Cynthia Levy, Ulus S Akarca, Mario Reis Alvares-da-Silva, Pietro Andreone, Marco Arrese, Christophe Corpechot, Sven M Francque iD, Michael A Heneghan, Pietro Invernizzi, David Jones und 21 weitere

New England Journal of Medicine · 29.02.2024 · 390 (9) · 795-805

DOI: 10.1056/nejmoa2306185 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 29.02.2024. Verfasst von Kris V Kowdley und 32 weiteren Autor:innen. Beteiligte Einrichtung: From Liver Institute Northwest, Seattle (K.V.K.); the Division of Gastroenterology and Hepatology, UC Davis School of Medicine, Sacramento (C.L.B.); …. Hauptthemen laut MEDLINE: Chalcones, Gastrointestinal Agents, Liver Cirrhosis, Biliary, Peroxisome Proliferator-Activated Receptors. Die Arbeit wurde bisher 321-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Ipsen, GENFIT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChalconesGastrointestinal AgentsLiver Cirrhosis, BiliaryPeroxisome Proliferator-Activated ReceptorsPropionatesHumansAdministration, OralAlkaline PhosphataseBilirubinCholestasisDouble-Blind MethodPPAR alphaPPAR deltaPruritusTreatment OutcomeUrsodeoxycholic AcidCholagogues and Choleretics

Substanzen

2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acidAlkaline PhosphataseBilirubinChalconesGastrointestinal AgentsPeroxisome Proliferator-Activated ReceptorsPPAR alphaPPAR deltaPropionatesUrsodeoxycholic Acid

Autor:innen und Institutionen

  • From Liver Institute Northwest, Seattle (K.V.K.); the Division of Gastroenterology and Hepatology, UC Davis School of Medicine, Sacramento (C.L.B.); Schiff Center for Liver Diseases, University of Miami, Miami (C.L.); t…

ORCID-Profile: Sven M Francque, Jörn M Schattenberg

Förderung

  • Ipsen
  • GENFIT

Zitieren

APA

Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., Invernizzi, P., Jones, D., Kruger, F. C., Lawitz, E., Mayo, M. J., Shiffman, M. L., Swain, M. G., Valera, J. M., Vargas, V., …, & ELATIVE Study Investigators' Group (2024). Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. New England Journal of Medicine, 390(9), 795-805. https://doi.org/10.1056/nejmoa2306185

Vancouver

Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, et al. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. New England Journal of Medicine. 2024;390(9):795-805. doi:10.1056/nejmoa2306185

BibTeX
@article{Kowdley2024,
  author = {Kowdley, Kris V and Bowlus, Christopher L and Levy, Cynthia and Akarca, Ulus S and Alvares-da-Silva, Mario Reis and Andreone, Pietro and Arrese, Marco and Corpechot, Christophe and Francque, Sven M and Heneghan, Michael A and Invernizzi, Pietro and Jones, David and Kruger, Frederik C and Lawitz, Eric and Mayo, Marlyn J and Shiffman, Mitchell L and Swain, Mark G and Valera, José Miguel and Vargas, Victor and Vierling, John M and Villamil, Alejandra and Addy, Carol and Dietrich, Julie and Germain, Jean-Michel and Mazain, Sarah and Rafailovic, Dragutin and Taddé, Bachirou and Miller, Benjamin and Shu, Jianfen and Zein, Claudia O and Schattenberg, Jörn M and ELATIVE Study Investigators’ Group, ELATIVE Study Investigators’ Group and ELATIVE Study Investigators' Group, ELATIVE Study Investigators' Group},
  title = {Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {9},
  pages = {795--805},
  doi = {10.1056/nejmoa2306185}
}
Kostenlos starten →